Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort

OBJECTIVE: To evaluate antithrombotic (AT) use in individuals with atrial fibrillation (AF) and at high risk of stroke (CHA(2)DS(2)-VASc score ≥2) and investigate whether pre-existing AT use may improve COVID-19 outcomes. METHODS: Individuals with AF and CHA(2)DS(2)-VASc score ≥2 on 1 January 2020 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Handy, Alex, Banerjee, Amitava, Wood, Angela M, Dale, Caroline, Sudlow, Cathie L M, Tomlinson, Christopher, Bean, Daniel, Thygesen, Johan H, Mizani, Mehrdad A, Katsoulis, Michail, Takhar, Rohan, Hollings, Sam, Denaxas, Spiros, Walker, Venexia, Dobson, Richard, Sofat, Reecha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Cardiac Risk Factors and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931797/
https://www.ncbi.nlm.nih.gov/pubmed/35273122
http://dx.doi.org/10.1136/heartjnl-2021-320325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931797/
https://www.ncbi.nlm.nih.gov/pubmed/35273122
http://dx.doi.org/10.1136/heartjnl-2021-320325

Ejemplares similares